The management of dermatomyositis is complex and needs to be tailored according to age, severity of muscle and skin, as well as systemic involvement. Systemic corticosteroids form the mainstay of therapy for myositis, supported by steroid-sparing immunosuppressive agents such as methotrexate, mycophenolate mofetil, or azathioprine. Cutaneous lesions often respond very well to antimalarials and topical agents, though recalcitrant cases may sometimes require systemic immunosuppressives or biologic therapies. Emerging treatments include Janus kinase inhibitors like tofacitinib and other biologics, and they show promise in refractory cases.